

# Applied Survival Analysis Using R

## Chapter 11: Sample Size Determination for Survival Studies

Qi Guo

Department of Mathematical Sciences  
The University of Texas at Dallas

April, 19 2019

- 1 Power and Sample Size for a Single Arm Study
- 2 Determining the Probability of Death in a Clinical Trial
- 3 Sample Size for Comparing Two Exponential Survival Distributions
- 4 Determining the Probability of Death from a Survival Curve Estimate
- 5 Using Simulations to Estimate Power

# Determinate the sample size

- Deciding how many subjects to include in a randomized clinical trial is a key component of its design.
- In survival analysis, there are two additional factors that one must specify regarding the *censoring mechanism* and the *particular* survival distributions.
  - Specify what parametric survival model one is using, allows for *determining the number of deaths* (or events) required to meet the power and other design specifications.
  - Administrative reasons, provide an estimate of the number of patients that need to be entered into the trial to *produce the required number of deaths*.

# Hypothesis Test

- The hypothesis test is  $H_0 : \lambda = \lambda_0$  versus  $H_A : \lambda = \lambda_A$ , and the  $H_0$  mean is  $\mu_0 = 1/\lambda_0$  and  $H_A$  mean is  $\mu_A = 1/\lambda_A$ , so the treatment(hazard) ratio is  $\Delta = \mu_A/\mu_0 = \lambda_0/\lambda_A$ .
- The most direct way to derive a sample size formula is based on a **Wald test**, transform to let  $\theta = \log(\mu) = -\log(\lambda)$ , then we can express the log-likelihood function as:

$$\ell(\theta) = d \log \lambda - \lambda V = -\theta d - V e^{-\theta} \quad (1)$$

and in Chapter we have shown the m.l.e  $\hat{\theta} = \log(V/d)$  and  $\text{var}(\hat{\theta}) \approx 1/d$ , where  $d = \sum \delta_i$  and  $V = \sum t_i$ , the number of death and total patient time.

- So now we can use  $\hat{\theta}$  as our test statistic, reject  $H_0$  in favor of  $H_A$  if  $\hat{\theta} > k$  for some constant  $k$ .

# Number of deaths to achieve

- The significance level of the test, or *Type I error*, is  $\alpha = \Pr(\hat{\theta} > k | \theta = \theta_0)$
- Using a normalizing transformation,

$$Z = \frac{\hat{\theta} - \mu}{1/\sqrt{d}} \quad (2)$$

so

$$\alpha = \Pr\left(Z > \frac{k - \theta_0}{1/\sqrt{d}}\right) \quad (3)$$

Hence

$$k = \theta_0 + \frac{z_\alpha}{\sqrt{d}} \quad (4)$$

# Number of deaths to achieve

- The power of the test is given by:

$$1 - \beta = Pr(\hat{\theta} > k | \theta = \theta_A) = Pr\left(Z > \frac{k - \theta_A}{1/\sqrt{d}}\right) \quad (5)$$

so

$$-z_\beta = \sqrt{d} \left( \theta_0 + \frac{z_\alpha}{\sqrt{d}} - \theta_A \right) \quad (6)$$

Solving for  $d$  we have:

$$d = \frac{(z_\beta + z_\alpha)^2}{(\theta_A - \theta_0)^2} = \frac{(z_\beta + z_\alpha)^2}{(\log \Delta)^2} \quad (7)$$

since  $\log(\Delta) = \log(\lambda_0) - \log(\lambda_A)$

- This gives us *the number of deaths* needed to achieve the specified power, *not the number of patients*.

## In R

- Compute the number of deaths based on (7)

```

1 > expLogMeanDeaths <- function(Delta, alpha, pwr) {
2   z.alpha <- qnorm(alpha, lower.tail=F)
3   z.beta <- qnorm(1-pwr, lower.tail=F)
4   num <- (z.alpha + z.beta)^2
5   denom <- (log(Delta))^2
6   dd <- num/denom
7   dd }

```

- We use the “qnorm” function to compute  $z_\alpha$  and  $z_\beta$ .

```

1 expLikeRatio <- function(d, alpha, pwr) {
2   num <- qchisq(alpha, df=(2*d), lower.tail=F)
3   denom <- qchisq(pwr, df=(2*d), lower.tail=F)
4   Delta <- num/denom
5   Delta }

```

# Estimate of the proportion of death

- We need to provide an estimate of the proportion  $\pi$  of patients who will die by the time of analysis. If all patients entered at the same time, we would simply have  $\pi = 1 - S(t, \lambda)$ , where  $t$  is the *follow-up* time.
- Patients actually enter over *an accrual period* of length  $a$ , after accrual to the trial has ended, they are followed for an *additional time*  $f$ .
- A patient who enters at time  $t = 0$  will have failure probability  $\pi(0) = 1 - S(a + f, \lambda)$ , so a patient who enters at time  $a$ ,  $\pi(a) = 1 - S(f, \lambda)$



# Estimate of the proportion of death

- Patients enter uniformly between times 0 and  $a$ , so that the patient entry follows a *Uniform(0,a)distribution*.
- Then the probability of death  $\pi$  is obtained by averaging over these times, so that a patient that enters at time  $t$  is followed for additional time  $a + f - t$ .

$$\pi = \int_0^a \frac{1}{a} Pr(\text{death} \mid \text{enter at time } t) dt \quad (8)$$

or just  $\mu = a + f - t$

$$\pi = \int_0^a \frac{1}{a} (1 - S(a + f - t; \lambda)) dt = 1 - \frac{1}{a} \int_a^{a+f} S(\mu; \lambda) d\mu \quad (9)$$

- Assuming an exponential distribution,  $S(\mu; \lambda) = e^{-\lambda\mu}$

$$\pi = 1 - \frac{1}{a\lambda} \{e^{-\lambda f} - e^{-\lambda(a+f)}\} \quad (10)$$

## In R

- Compute the probability of death:

```
1 prob.death <- function(lambda, accrual, followup) {
2   probDeath <- 1 - (1/(accrual*lambda))* (exp(-lambda*followup) -
3   exp(-lambda*(accrual + followup)))
4   probDeath}
```

- $H_1 : \lambda = 0.10, a = 2$  and  $f = 3$  years

```
1 > prob.death(lambda=0.10, accrual=2, followup=3)
2 [1] 0.3285622
```

- Previously we found that 38 deaths were needed, then Then the number of patients needed is approximately  $38/0.3285622 = 115.6$

# Prerequisites

- Let  $p$  denote the proportion of patients randomized to the control group, denote by  $n$  the total number of patients in the trial, and we have  $n_0 = np$  and  $n_1 = n(1 - p)$  control and experimental patients, respectively.
- When the trial has been completed, we will observe  $d_0$  and  $d_1$  deaths in the control and experimental groups, and total patient times of  $V_0 = \sum t_{0i}$  and  $V_1 = \sum t_{1i}$ .
- The maximum likelihood estimates of the hazards  $\hat{\lambda}_0 = d_0/V_0$  and  $\hat{\lambda}_1 = d_1/V_1$ .
- Compare the two distributions, use  $\delta = \log \Delta = \log \lambda_0 - \log \lambda_1$

# Number of death to achieve

- Based on maximum likelihood theory

$$\text{var}(\hat{\delta}) = \sigma^2 = \frac{1}{n_0\pi_0} + \frac{1}{n_1\pi_1} = \frac{1}{np(1-p)} \cdot \frac{p\pi_0 + (1-p)\pi_1}{\pi_0\pi_1} \quad (11)$$

- where  $\pi_0$  and  $\pi_1$  are the probabilities of death in the control and treatment groups, define a new

$$\tilde{\pi} = \left( \frac{p\pi_0 + (1-p)\pi_1}{\pi_0\pi_1} \right)^{-1} = \left( \frac{p}{\pi_1} + \frac{1-p}{\pi_0} \right)^{-1} \quad (12)$$

- $\tilde{\pi}$  is a weighted harmonic mean of  $\pi_0$  and  $\pi_1$

# Number of death to achieve

- Approximate the weighted mean  $\bar{\pi} = p\pi_0 + (1 - p)\pi_1$ , so

$$\text{var}(\hat{\delta}) = \sigma^2 = \frac{1}{np(1-p)} \cdot \bar{\pi}^{-1} \quad (13)$$

- Expressing the test in terms of  $\delta = \log \Delta$ , we reject  $H_0 : \delta = 0$  in favor of  $H_A : \delta > 0$  if  $\hat{\delta} > k$  for some constant  $k$ .
- By the similar argument before, we get  $n$ :

$$n = \frac{(z_\alpha + z_\beta)^2}{\delta^2 p(1-p)\bar{\pi}} \quad (14)$$

- The required number of patients is the number of deaths

$$d = \frac{(z_\alpha + z_\beta)^2}{\delta^2 p(1-p)} \quad (15)$$

# Approximate

- Given a survival function  $\hat{S}(t)$  there are a number of ways of evaluating the integral in (9)
- Approximate the integral by evaluating  $\hat{S}(t)$  for a patient entering at time 0,  $a/2$ , and  $a$ , use some results from elementary integral calculus.
- The trapezoidal rule:*

$$\pi_s \approx 1 - \frac{1}{6} \{ \hat{S}(a+f) + 4\hat{S}(\frac{a}{2} + f) + \hat{S}(f) \} \quad (16)$$

- The most accurate method is to evaluate the integral numerically

$$\pi_r = \sum_{t_{(i)}: f < t_{(i)} \leq a+f} [\hat{S}(a+f - t_{(i)}) \cdot (t_{(i)} - t_{(i-1)})] \quad (17)$$

## In R

- Using the data “gastricXelox” from Chapter 3
- Extract the failure times and survival probabilities:

```
1 library(survival)
2 result.km <- survfit(Surv(timeMonths, delta) ~ 1,
3   conf.type="log-log")
4 timesXe <- result.km$time
5 survXe <- result.km$surv
```

- Set up the accrual and follow-up times, and select the portion of the failure times in the interval from  $f$  to  $a + f$

```
1 accrual <- 12
2 followup <- 6
3 times.use <- c(followup, timesXe[timesXe >= followup &
4   timesXe <= accrual + followup])
5 surv.use <- summary(result.km, times=times.use)$surv
```

- Finally, we use the “diff” function to get the widths of the rectangles.

## In R




Fig. 11.2 Portion of the Kaplan-Meier plot (Fig. 3.6) showing the rectangles needed for the integral in Eq. 11.22

```

1 > surv.simpson <- summary(result.km,
2 times=c(followup, accrual/2 + followup, accrual+followup))
3 > surv.simpson$surv
4 [1] 0.6458333 0.4782609 0.3034080
5 #We evaluate the probability of death:
6 > pi.simpson <- 1 - (1/6)*(surv.simpson[1] + 4*surv.simpson[2] +
7 surv.simpson[3])
8 > pi.simpson
9 [1] 0.5229525

```

- So the estimate of the probability of death is  $\pi_s = 0.523$



# Simulation

- 1 Suppose that we are computing *power* for a two arm randomized clinical trial comparing a *standard therapy* to an *experimental therapy*
- 2 Select a parametric distribution that approximates the survival of patients given the standard therapy, and specify a hazard ratio to detect.
- 3 Model the entry of patients over a specified accrual period, randomization to *either of the two arms*, and follow them until death or until they are censored
- 4 Compute a test statistic and p-value using, typically, *a log-rank test*.
- 5 Repeat this process a large number of times, and observe the proportion of times we reject the null hypothesis of *no treatment difference*, this is the *estimated power*.

# Example

## Example 11.1

Determine if an *experimental agent* can *increase* the time to death from prostate cancer among patients diagnosed with advanced localized prostate cancer. First specify the eligibility criteria, and to use the data in “prostateSurvival” to determine the survival distribution to select a Weibull distribution that matches the data. Specifically, consider men aged 66 to 74 with newly diagnosed, poorly differentiated, stage T2 prostate cancer, and find a Weibull distribution that matches the survival proportions of these patients at four and eight years.

# Example

```

1 > attach(prostateSurvival)
2 > prost.66to74.poor <- prostateSurvival[{{grade == "poor"} &
3 {{ageGroup == "70-74"} | {ageGroup == "66-69"}} &
4 {stage == "T2"}},]
5 > library(survival)
6 > status.prost <- as.numeric(prost.66to74.poor$status == 1)
7 > result.prost.survfit <- survfit(Surv(survTime, status.
8 prost) ~ 1, data=prost.66to74.poor)
9 > summary(result.prost.survfit, time=c(48, 96))
10 time    n.risk    n.event   survival   std.err   lower95% CI   upper95% CI
11  48         154         16     0.931     0.0171     0.898        0.965
12  96          26         17     0.717     0.0565     0.615        0.837

```

- Find a Weibull distribution that matches the survival probabilities at these two times.

```

1 library(Hmisc)
2 Weib.p <- Weibull2(c(4,8),c(0.931,0.717))

```

# Example

- Take a *peek* for the survival probability base on Weibull distribution

```
1 > Weib.p<- function(times = NULL, alpha = 0.0033021237632906,
2   gamma = 2.21819823268731) {
3   exp(-alpha * (times^gamma))
4 }
```


- Define functions using the “Quantile2” to specify the control survival function (“Weib.p”) and the hazard ratio(0.75), indicate that the experimental agent would reduce the hazard of prostate cancer mortality by 25 %

```
1 ff <- Quantile2(Weib.p,hratio=function(x) 0.75)
2 plot(ff, xlim=c(0,8))
```

- Specify names for the two survival distributions and extract them from “ff” (Fig. 11.3).

```
1 rcontrol <- function(n) ff(n, what='control')
2 rintervention <- function(n) ff(n, what='intervention')
```

# Example



**Fig. 11.2** Portion of the Kaplan-Meier plot (Fig. 3.6) showing the rectangles needed for the integral in Eq. 11.2.2

- Specify the censoring distribution “`rcens`” using the R function “`runif`” as follows (using time in years):

```
1 rcens <- function(n) runif(n, 5, 8)
```

# Example

- Carry out the power simulation using “`spower`”. Here we specify that there will be  $nc = 1500$  patients enrolled in the *control arm* and  $ni = 1500$  in the *intervention arm*, simulate  $nc = 1000$  data sets, and carry out a log-rank test at the 0.025

```
1 > spower(rcontrol, rintervention, rcens, nc=1500, ni=1500,
2 test=logrank, nsim=1000, alpha=0.025)
3 [1] 0.827
```

- The result of the function, 0.827, is the power of the test, verify the significance level of the test by specifying “`rcontrol`” as both the control and intervention distribution

```
1 > spower(rcontrol, rcontrol, rcens, nc=1500, ni=1500, test=logrank,
2 [1] 0.028
```

- Empirical Type I error rate is 2.8 %

# Example

- This way can *accommodate deviations* from the usual assumptions of uniform accrual, proportional hazards, and perfect patient compliance
- Suppose we expect that 10% of the patients on the intervention arm will be non-compliant, in that they to not take the experimental agent.
- Include that *noncompliance factor* in the simulation via the “dropout” argument in the “Quantile2” function.

```

1 > ff.dropout <- Quantile2(Weib.p,hratio=function(x) 0.75,
2 dropout=function(x) 0.10)
3 > rcontrol <- function(n) ff.dropout(n, what=?control?)
4 > rintervention <- function(n) ff.dropout(n, what=?intervention?)
5 > spower(rcontrol, rintervention, rcens, nc=350, ni=350,
6 test=logrank, nsim=1000, alpha=0.025)
7 [1] 0.734

```

- We see that the noncompliance has resulted in a loss of power, from 82.7% to 73.4%.